Jacobson Pharma Corporation Limited (2633) AI Stock Analysis

• Market Cap: HK$2.45B
• Dividend Yield: 15.16%
• Average Volume (3M): 821.71K
• Price to Earnings (P/E): 8.5
• Beta (1Y): 0.15
• Revenue Growth: -1.88%
• EPS Growth: 17.57%
• Country: HK
• Employees: 1,730
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.07
• Shares Outstanding: 2,000,221,000
• 10 Day Avg. Volume: 1,775,382
• 30 Day Avg. Volume: 821,706
• PEG Ratio: 0.06
• Price to Book (P/B): 0.96
• Price to Sales (P/S): 1.49
• P/FCF Ratio: 8.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: HK$1.50 ▲(18.11% Upside)

Jacobson Pharma Corporation Limited has a strong financial foundation with solid profitability and effective cash management. The valuation is attractive with a reasonable P/E ratio and a high dividend yield. However, technical indicators suggest mixed market momentum, which could pose short-term challenges. The absence of recent earnings call data and corporate events limits further insights.

Positive Factors

Revenue Growth

Positive revenue growth indicates expanding market reach and product adoption, supporting long-term business sustainability despite recent fluctuations.

Cash Generation

Strong cash generation supports reinvestment and shareholder returns, enhancing financial stability and growth potential over time.

Profitability

Consistent profitability growth demonstrates effective cost management and operational efficiency, contributing to sustainable financial health.

Negative Factors

Debt Levels

Moderate leverage requires careful management to avoid constraints on financial flexibility, potentially impacting future growth and stability.

Revenue Fluctuations

Revenue fluctuations can signal market challenges or operational issues, necessitating strategic adjustments to maintain growth momentum.

Capital Expenditures

Fluctuating capital expenditures can impact long-term investment strategies, potentially affecting the company's ability to sustain growth and innovation.

Jacobson Pharma Corporation Limited Business Overview & Revenue Model

Company Description

Jacobson Pharma Corporation Limited, through its subsidiaries, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally. The company offers generic drugs for various therapeutic categories, including the respiratory, cardiovascular, central nervous system, gastrointestinal, genito-urinary, musculoskeletal, endocrine and metabolic, dermatological, anti-allergics, scar treatment, oral anti-diabetics, and anti-infective, as well as arsenic trioxide oral solutions, rosuvastatin tablets, and atorvastatin tablets. It also provides branded medicines; health and wellness products; and proprietary Chinese medicines, such as Po Chai pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling oil, Contractubex, Doan's Ointment, and Col-gan tablets. In addition, it engages in the trading of medical supplies; procurement of packaging materials; sale of healthcare and herbal products; research and development; and property holding activities. Jacobson Pharma Corporation Limited sells its products to hospitals and clinics, and registered pharmacies, as well as to doctors in private and retail outlets, and trading companies. The company was incorporated in 2016 and is headquartered in Kwun Tong, Hong Kong. Jacobson Pharma Corporation Limited is a subsidiary of Kingshill Development Limited.

How the Company Makes Money

Jacobson Pharma generates revenue primarily through the sale of its pharmaceutical products, which encompass generic medications and proprietary drugs. The company's revenue model is built on a mix of direct sales to hospitals, pharmacies, and healthcare institutions, as well as partnerships with distributors and other pharmaceutical companies for broader market reach. Significant revenue streams include prescription drugs, OTC products, and health supplements. Additionally, the company benefits from collaborations with healthcare organizations and participation in government tenders, which can provide substantial contracts and enhance its market presence. Ongoing investment in research and development also positions Jacobson Pharma to introduce new products and expand its therapeutic offerings, further contributing to its earnings potential.

Jacobson Pharma Corporation Limited Financial Statement Overview

Summary

Jacobson Pharma Corporation Limited exhibits solid financial performance across its income statement, balance sheet, and cash flow statement. The company demonstrates strong profitability, efficient operations, and effective cash management. While growth trends are generally positive, attention to revenue fluctuations and debt levels will be crucial for sustaining long-term growth and stability.

Income Statement

Jacobson Pharma Corporation Limited has demonstrated a strong performance in its income statement. The gross profit margin is healthy, indicating effective cost management. The net profit margin reflects profitability, with consistent growth in net income over the years. Revenue growth has been positive, though there was a slight decline in the most recent year. EBIT and EBITDA margins are solid, showing operational efficiency. Overall, the company maintains a robust financial health in its income statement metrics.

Balance Sheet

The balance sheet of Jacobson Pharma indicates a stable financial position with a solid equity base. The debt-to-equity ratio suggests a moderate level of leverage, manageable within industry norms. Return on Equity (ROE) is favorable, showing effective use of equity capital to generate profits. The equity ratio is strong, signifying a substantial proportion of assets financed by shareholders' equity. However, the company should monitor its debt levels to ensure long-term financial flexibility.

Cash Flow

Cash flow analysis reveals a strong operating cash flow, indicating excellent cash generation capability. The free cash flow has grown consistently, supporting reinvestment opportunities and shareholder returns. Ratios of operating and free cash flow to net income demonstrate effective cash management. The company has improved its free cash flow generation, although capital expenditures have seen fluctuations. Overall, the cash flow statement highlights robust cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.56B	1.58B	1.47B	1.79B	1.60B	1.45B
Gross Profit	670.87M	692.94M	620.48M	747.17M	620.52M	534.15M
EBITDA	503.26M	558.87M	475.11M	462.04M	415.49M	377.20M
Net Income	253.22M	300.83M	266.97M	251.04M	177.67M	173.71M
Balance Sheet
Total Assets	3.61B	3.65B	3.49B	5.38B	4.76B	4.87B
Cash, Cash Equivalents and Short-Term Investments	563.79M	509.05M	411.94M	1.04B	478.65M	480.35M
Total Debt	699.85M	773.21M	749.38M	1.60B	1.41B	1.65B
Total Liabilities	1.15B	1.17B	1.09B	2.12B	1.80B	2.01B
Stockholders Equity	2.43B	2.45B	2.37B	2.74B	2.49B	2.39B
Cash Flow
Free Cash Flow	429.97M	278.39M	354.85M	585.23M	345.89M	347.99M
Operating Cash Flow	495.44M	526.78M	484.36M	648.24M	409.76M	411.35M
Investing Cash Flow	-217.31M	-297.76M	43.34M	-44.09M	-52.75M	-375.40M
Financing Cash Flow	-733.81M	-131.30M	-1.05B	-45.64M	-357.89M	21.36M

Jacobson Pharma Corporation Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.27
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2633, the sentiment is Negative. The current price of 1.27 is below the 20-day moving average (MA) of 1.30, below the 50-day MA of 1.36, and below the 200-day MA of 1.31, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 40.84 is Neutral, neither overbought nor oversold. The STOCH value of 65.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2633.

Jacobson Pharma Corporation Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6896	75 Outperform	HK$2.39B	8.24	21.47%	15.92%	-2.70%	2.19%
2161	75 Outperform	HK$2.19B	10.05	20.78%	10.06%	12.83%	36.12%
2877	73 Outperform	HK$6.21B	6.96	10.85%	6.06%	-20.64%	-25.39%
2348	72 Outperform	HK$1.82B	9.55	5.34%	5.21%	2.89%	-68.83%
2633	69 Neutral	HK$2.45B	8.49	12.97%	15.16%	-1.88%	17.57%
0950	64 Neutral	HK$995.13M	10.17	5.35%	2.80%	19.80%	55.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Jacobson Pharma Corporation Limited Corporate Events

Jacobson Pharma Reports Interim Results with Increased Shareholder Dividends

Jacobson Pharma Corporation Limited reported its interim results for the six months ended 30 September 2025, showing a revenue decrease of 5.4% to HK$766.6 million compared to the same period in 2024. Despite a decline in revenue and operating profit, the company saw a 1.2% increase in profit attributable to equity shareholders, amounting to HK$142.0 million. The Board declared an interim dividend of HK4.25 cents per share, a 21.4% increase from the previous year, indicating a positive outlook for shareholders.

Jacobson Pharma Declares Interim Dividend for 2025

Jacobson Pharma Corporation Limited announced an interim dividend of HKD 0.0425 per share for the six months ending September 30, 2025, with a payment date set for December 18, 2025. This announcement reflects the company’s stable financial performance and commitment to providing shareholder value, potentially enhancing its market position and investor confidence.

Jacobson Pharma Schedules Board Meeting to Review Interim Results

Jacobson Pharma Corporation Limited has announced that its board of directors will meet on November 18, 2025, to review and approve the interim results for the six months ending September 30, 2025. The meeting will also consider the payment of an interim dividend and address other business matters, which could impact the company’s financial strategy and stakeholder interests.

Jacobson Pharma Announces New Europharm Licensing Agreement

Jacobson Pharma Corporation Limited has announced a new licensing agreement, the 2025 Europharm License Agreement, between its subsidiaries Europharm and Europharm HK. This agreement, effective from December 1, 2025, to January 27, 2028, involves Europharm granting Europharm HK a license to use part of its factory for a monthly fee. This transaction is categorized as a connected and continuing connected transaction under Hong Kong’s Listing Rules, impacting the company’s asset acquisition processes and reporting requirements.